ZBH

$92.52

Post-MarketAs of Mar 17, 8:00 PM UTC

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$92.52
Potential Downside
26.6%
Whystock Fair Value$67.88
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, inclu...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.06
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Strong income play. Yield provides a meaningful total return floor.
103.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
5.60%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.90

Recent News

Barchart
Mar 16, 2026

How Is Zimmer Biomet Holdings’ Stock Performance Compared to Other Medical Devices Stocks?

Zimmer Biomet Holdings stock has lagged other medical device stocks over the past year, while analysts are neutral about its prospects.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 15, 2026

Zimmer Biomet (ZBH) Valuation Check After Earnings Beat And Updated Growth Outlook

Zimmer Biomet Holdings (ZBH) just reported fourth quarter 2025 results that topped adjusted earnings expectations, alongside 10.9% year over year net sales growth and new guidance for 2026 revenue and earnings. See our latest analysis for Zimmer Biomet Holdings. At a share price of $93.20, Zimmer Biomet’s 1-day share price return of 0.66% and 90-day share price return of 1.76% sit against a 1-year total shareholder return decline of 14.41%, which points to some recent momentum after a weaker...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead?

ISRG targets cardiac surgery as a long-term da Vinci 5 growth driver after FDA clearance, eyeing nearly 160,000 potential procedures in cleared markets vs approximately 17,000 today.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 11, 2026

3 Healthcare Stocks We Think Twice About

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 4.1% over the past six months, almost identical to the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.